A Theranostic Approach to Imaging and Treating Melanoma with 203Pb/212Pb-Labeled Antibody Targeting Melanin
Author:
Jiao Rubin1, Allen Kevin J. H.1, Malo Mackenzie E.1ORCID, Yilmaz Orhan1, Wilson John2, Nelson Bryce J. B.2, Wuest Frank23, Dadachova Ekaterina1
Affiliation:
1. College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada 2. Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada 3. Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB T6G 2E1, Canada
Abstract
Metastatic melanoma is a deadly disease that claims thousands of lives each year despite the introduction of several immunotherapeutic agents into the clinic over the past decade, inspiring the development of novel therapeutics and the exploration of combination therapies. Our investigations target melanin pigment with melanin-specific radiolabeled antibodies as a strategy to treat metastatic melanoma. In this study, a theranostic approach was applied by first labeling a chimeric antibody targeting melanin, c8C3, with the SPECT radionuclide 203Pb for microSPECT/CT imaging of C57Bl6 mice bearing B16-F10 melanoma tumors. Imaging was followed by radioimmunotherapy (RIT), whereby the c8C3 antibody is radiolabeled with a 212Pb/212Bi “in vivo generator”, which emits cytotoxic alpha particles. Using microSPECT/CT, we collected sequential images of B16-F10 murine tumors to investigate antibody biodistribution. Treatment with the 212Pb/212Bi-labeled c8C3 antibody demonstrated a dose-response in tumor growth rate in the 5–10 µCi dose range when compared to the untreated and radiolabeled control antibody and a significant prolongation in survival. No hematologic or systemic toxicity of the treatment was observed. However, administration of higher doses resulted in a biphasic tumor dose response, with the efficacy of treatment decreasing when the administered doses exceeded 10 µCi. These results underline the need for more pre-clinical investigation of targeting melanin with 212Pb-labeled antibodies before the clinical utility of such an approach can be assessed.
Funder
Continuous Research Fund
Subject
Cancer Research,Oncology
Reference40 articles.
1. American Cancer Society (2022, March 04). Melanoma of the Skin. Available online: https://cancerstatisticscenter.cancer.org/#!/cancer-site/Melanoma%20of%20the%20skin. 2. National Cancer Institute (2022, March 04). Cancer Statistics, Available online: https://www.cancer.gov/about-cancer/understanding/statistics#:~:text=The%20most%20common%20cancers%20(listed,endometrial%20cancer%2C%20leukemia%2C%20pancreatic%20cancer. 3. Ragusa, F., Ferrari, S.M., Elia, G., Paparo, S.R., Balestri, E., Botrini, C., Patrizio, A., Mazzi, V., Guglielmi, G., and Foddis, R. (2022). Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. Int. J. Mol. Sci., 23. 4. A guide to cancer immunotherapy: From T cell basic science to clinical practice;Waldman;Nat. Rev. Immunol.,2020 5. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma;Hodi;N. Engl. J. Med.,2010
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|